Fractionated stereotactic radiation therapy improves cranial neuropathies in patients with skull base meningiomas: a retrospective cohort study
- Xinglei Shen1, 7Email author,
- David W Andrews2,
- Robert C Sergott3,
- James J Evans2,
- Walter J Curran4,
- Mitchell Machtay5,
- Ruben Fragoso6,
- Harriet Eldredge1, 8,
- Colin E Champ1, 8,
- Matthew Witek1, 8,
- Mark V Mishra1, 8,
- Adam P Dicker1, 8 and
- Maria Werner-Wasik1, 8
© Shen et al.; licensee BioMed Central Ltd. 2012
Received: 19 March 2012
Accepted: 18 December 2012
Published: 28 December 2012
Skull base meningiomas commonly present with cranial neuropathies. Fractionated stereotactic radiation therapy (FSRT) has been used to treat these tumors with excellent local control, but rates of improvement in cranial neuropathies have not been well defined. We review the experience at Thomas Jefferson University using FSRT in the management of these patients with a focus on symptom outcomes.
We identified 225 cases of skull base meningiomas treated with FSRT at Thomas Jefferson University from 1994 through 2009. The target volume was the enhancing tumor, treated to a standard prescription dose of 54 Gy. Symptoms at the time of RT were classified based on the cranial nerve affected. Logistic regression was performed to determine predictors of symptom improvement after FSRT.
The median follow-up time was 4.4 years. In 92% of cases, patients were symptomatic at the time of RT; the most common were impaired visual field/acuity (58%) or extraocular movements (34%). After FSRT, durable improvement of at least one symptom occurred in 57% of cases, including 40% of visual acuity/visual field deficits, and 40% of diplopia/ptosis deficits. Of all symptomatic patients, 27% experienced improvement of at least one symptom within 2 months of the end of RT.
FSRT is very effective in achieving improvement of cranial neuropathies from skull base meningiomas, particularly visual symptoms. Over half of treated patients experience a durable improvement of at least one symptom, frequently within 2 months from the end of RT.
KeywordsFractionated stereotactic radiation therapy Meningioma Symptom Outcome Skull base
Clinical target volume
Gross tumor volume
Fractionated stereotactic radiation therapy
Intensity modulated radiation therapy
Planning target volume
Radiation induced optic neuritis
Meningiomas are benign tumors which account for approximately 25% of primary intracranial tumors . A significant proportion arises in the skull base region, where they are often difficult to access surgically and frequently cause cranial neuropathies. Definitive treatment recommendations for these tumors include radiation therapy (RT) and surgery (with post-operative RT after subtotal resection) [2, 3]. Following complete or subtotal resection without RT, 5 year progression free survival ranges from 81-95% [2–4].
RT can provide excellent local control in the definitive and post-operative settings. Single institution series of fractionated RT using either 3-D conformal RT [5, 6], intensity modulated radiation therapy (IMRT) , or fractionated stereotactic radiation therapy (FSRT) [8–10] have reported local control rates of 90-100%. Stereotactic radiosurgery (SRS) with Gamma Knife or linear accelerator (LINAC) based SRS have also resulted in excellent local control [11–13].
Although local control data have been extensively described, most series fail to evaluate symptomatic outcomes for these patients. An overview of published literature indicated that 14-44% of patients have clinical neurological improvement after FSRT, and up to 95% have stabilization of neurologic symptoms . However, a paucity of literature exists with regards to details of symptom outcomes, such as timing of symptom improvement, durability of symptom improvement, and prognostic factors.
At our institution, we have treated skull base meningiomas both definitively and post-operatively with FSRT since 1994. Our institutional philosophy has been to preferentially treat skull base meningiomas with FSRT instead of SRS based on the theoretical radiobiological advantage of fractionation to achieve greater sparing and recovery of sensitive normal structures such as the optic apparatus. We have observed an unexpected rate of durable symptomatic improvement during and soon after FSRT treatment. This report will review our experience of treating patients with skull base meningiomas with FSRT, focusing our analysis and discussion on symptom outcomes.
We reviewed all patients with skull base meningiomas treated with FSRT from 1/1/1994 to 3/1/2009. Skull base meningiomas were defined as any clinically or pathologically diagnosed meningioma which involved the cavernous sinus, sphenoid, clinoid, sella, suprasellar region, cerebellopontine angle, petroclival region, foramen magnum, clivus, or designated as skull base, not otherwise specified (which tended to be large tumors encompassing multiple regions). For analysis of local control, we classified patients into four treatment categories: RT alone, adjuvant RT (after subtotal or near total resection), RT for progression/recurrence after surgery, or re-irradiation (with or without prior surgery).
All patients were treated on a dedicated stereotactic linear accelerator (Varian SR600 or Novalis TX). Gross tumor volume (GTV) was equivalent to clinical target volume (CTV) and planning target volume (PTV), and was defined as the contrast enhancing tumor only. Our standard prescription dose was 54 Gy (range 10 – 60 Gy, median 52.2 Gy) in 1.8 or 2.0 Gy/fraction. Dose was reduced in 56% of cases when the optic chiasm dose exceeded 56–57 Gy, or in re-irradiation cases. Prior to 2004, treatment planning was performed on the Radionics XKnife (Radionics, Inc., Burlington, MA) treatment planning system, with multi-isocenter plans (median 79% isodose line) using spherical collimators and Gill-Thomas-Cosman frames for patient immobilization. After 2004, patients were planned with BrainLab (BrainLAB AG, Feldkirchen, Germany) treatment planning system with single isocenter conformal plans using 5 dynamic arcs (median 90% isodose line), and thermoplastic mask for patient immobilization with position verification using ExacTrac kV daily imaging. Static stereotactic intensity modulated radiation therapy (IMRT) was introduced in 2004, and was generally used for large tumors with eccentric shapes or those close to critical structures.
Patients followed up with a radiation oncologist at 6 weeks after completion of RT. Subsequent follow-up visits with either a radiation oncologist or neurosurgeon occurred at 3 months, 6 months, and 1 year, and then yearly and bi-annually up to 10 years, and then per patient preference afterwards. Length of follow-up was defined as time from the start of RT to the last follow-up with radiation oncology or neurosurgery. Time to progression was defined as the time from start of RT to the date of first radiographic evidence of progression.
Symptoms and toxicity
Symptoms were classified into major categories based on the cranial nerves (CN) involved: visual field/visual acuity (CN2), extra-ocular movements/ptosis (CN3, 4, 6), facial sensation (CN5), facial strength (CN7), hearing/balance/tinnitus (CN8), swallowing/tongue weakness (CN9-12), and other (including long tract signs and symptoms due to mass effect such as headache and proptosis). We included all symptoms at time of RT, including those which first appeared in the post-operatively. Duration of symptoms prior to RT was calculated from date of initial symptom presentation to start of RT. Durability of symptom improvement or worsening was defined as a continued subjective change or physical exam difference at the time of last followup compared to pre-RT baseline. Time to improvement and time to worsening were calculated from the start of radiotherapy to the date of change. Adverse events were defined as development of a new cranial neuropathy such as radiation induced optic neuritis (RION), trigeminal neuropathy, or other symptoms not associated with tumor progression. Radiographic findings of radiation necrosis were included as adverse events, regardless of symptoms.
Statistical analysis was performed using SAS v9.2 (SAS Institute Inc, Cary, NC). Freedom from progression was estimated using Kaplan-Meier method, with differences between treatment groups calculated using the log-rank test compared to the RT alone group. Events were censored at last follow-up. We used univariate and backwards stepwise multivariate Cox proportional hazards models to estimate the hazard ratios of factors associated with tumor progression. The initial multivariate model included age, sex, prior RT, midline or bilateral location, presence of symptoms at presentation, use of IMRT, use of BrainLab planning system, prior surgery, treatment group, GTV size, fraction size (≥2 Gy vs. < 2 Gy), total dose, time from diagnosis to RT, and pathologic grade, if known. A two sided α < 0.05 was considered significant.
Univariate and backwards stepwise logistic regression model was used to determine factors associated with any symptom improvement. Covariates in the initial multivariate model included duration of symptoms prior to RT, age, gender, GTV size, fraction size, total dose, prior surgery, re-irradiation, midline or bilateral location, use of IMRT, and use of BrainLab planning system. We used logistic regression to determine the odds ratio (OR) of worsening of symptoms events in cases with progression compared to those without progression. A two sided α <0.05 was considered significant.
Median Age (years)
60.7 (range 21–92)
Median Tumor Volume (cc)
8.7 (range 0.67 – 62.2)
Symptoms at time of Radiation
Intensity Modulate Radiation Therapy
Progression after surgery
No pathologic diagnosis
WHO grade I
WHO grade II
> 52.5 Gy
<= 52.2 Gy
Distribution of presenting symptoms at the time of radiation therapy
Number of cases
Percent of all cases*
Median duration (months)**
New symptom post-op***
Visual Acuity/Visual Field
Cranial Nerve III
Cranial Nerve IV
Cranial Nerve VI
Cranial Nerve IX -XII
Timing and durability of symptom improvement
Median time to improve (mo.)
Durability of improve*
Median time to worsening (mo.) (range)
0.1 - 30.1
0.2 - 98.2
0.6 - 128.7
0.5 - 85.9
0.6 - 58.6
2.5 - 102.7
1.1 - 42.8
1.9 - 64.9
2.1 - 2.7
2.5 - 82.8
2.8 - 2.8
2.8 - 114.0
2.4 - 4.6
Cranial Nerve IX-XII
4.2 - 5.6
6.4 - 31.5
0.5 - 5.6
2.4 - 20.3
Example of very early visual acuity improvement during fractionated stereotactic radiation therapy course
Time from start of RT (months)
Visual acuity left eye
Humphrey visual field (MSD/PD*) left eye
On treatment (27 Gy)
On treatment (32.4 Gy)
Symptoms and progression
Symptom worsening occurred more often in cases where tumors progressed (68% vs. 13%, p < 0.01). Patients with tumor progression had a 12 fold increased odds of symptoms worsening (OR 12.29 95% CI 4.6 – 32.6, p < 0.01). The most common presenting symptom, visual field/visual acuity deficit, worsened in 12 of 17 (70.6%) patients who ultimately experienced progression. Worsening of symptoms commonly preceded objective radiographic finding of tumor progression (data not shown).
Predictors of symptom improvement
Multivariate predictors of symptom improvement
Age (per 10 years older)
0.62 – 0.98
0.25 – 0.86
0.11 – 1.40
0.25 – 1.11
We noted 32 adverse events in 28 patients (12.5% cumulative incidence). The most common adverse events were radiation induced optic neuritis (n = 5, 2.2%), radiation necrosis (n = 5, 2.2%) and facila numbness or pain (n = 5, 2.2%). Additional adverse events included three cases of hypothyroidism, two cases each of diplopia, significant cognitive decline, and occipital neuralgia, and one case each of dysphagia, facial myoclonus, glossopharyngeal neuralgia, seizures,, diabetes insipitus, and vertigo.
We present the results of our institutional experience with FSRT for the treatment of skull base meningiomas. Our local control outcomes are consistent with other reports of 5 year progression free survival rates of 87–95.7% after treatment with either SRS [11–13, 15] or FSRT [8–11]. Since many of these patients are symptomatic at presentation (92% in our cohort) we feel that symptom outcome is a crucial end-point in addition to local control and overall survival, which tend to be universally excellent in published reports. This report adds to the existing literature on by providing a detailed analysis dissected by symptom domain in a large retrospective cohort. These patients were closely followed during RT, allowing detection of a high rate of symptom improvement early in the treatment course.
We found that in addition to providing excellent local control, FSRT resulted in durable symptom improvement of one or more symptoms in 57% of cases. For patients with reduced vision, FSRT durably improved or maintained vision in at least 71% of cases, demonstrating the utility of FSRT in function preservation. While less detailed, other series in the literature have also reported between a 5-46% rate of improvement in symptoms following radiation therapy with either SRS or FSRT [8, 9, 15, 16]. We have not attempted to compare these results with those reported from SRS or surgical series because =of multiple potential confounding factors such as case mix, recall bias and reporting bias.
We found a negative association between prior surgery, re-irradiation and increasing age with the likelihood of symptom improvement after FSRT. These finding suggest FSRT after prior definitive treatment is less likely to result in symptomatic improvements, particularly in older patients. Midline or bilateral location was a negative prognostic factor for symptom improvement, a finding which has not been reported previously. Midline and bilateral tumors were larger, received less radiation dose, and underwent resection prior to radiation more often. It is unclear whether this finding is the result of an intrinsic property of tumors of this region or a spurious finding as a result of multiple comparisons, and should be investigated in future studies. Of interest, despite evolving technology, the use of the BrainLab treatment planning system, a surrogate for patients treated prior to 2004 versus those treated after 2004, predict for either local control or symptom improvement.
When patient symptoms improved, they did so by the end of FSRT in one third of patients, and within two months of the end of FSRT in over half of patients. This observation of the early symptom improvement raises questions regarding the underlying mechanism. Such improvement was also reported in the literature to occur at 6 weeks after completion of IMRT  and FSRT . This time frame typically precedes radiographic shrinkage and likely occurs before the full tumoricidal effect of radiation. A placebo effect is unlikely to account for this symptoms relief, as patients were noted to have objective responses on cranial nerve examinations during weekly treatment visits. Although speculative, one possible explanation for restoration of cranial nerve function after radiation is re-distribution of vascular flow from tumor to the affected cranial nerve(s).
Conversely, while radiographic improvement does not necessarily correlate with symptomatic improvement, there was a strong relationship between radiographic tumor progression and symptom worsening. The mechanism of symptom worsening may differ from that of improvement. Indeed, the clinical finding of a new symptom may be an early indicator of radiographic progression.
Treatment was generally very well tolerated and adverse events were infrequent in our series, though estimates were conservative and included all possible treatment related events. Our reported rates of RION (2.2%) and radiation necrosis (2.2%) were low and may still over-estimate the actual adverse event rates, supporting FSRT as a safe treatment option.
Limitations to our study include limited documentation of symptom severity and relatively short median follow-up time. Although we recorded symptom severity, these were often recorded as subjective rather than objective measures. Some of patients did have objective measurement of symptom outcomes, such as with visual field testing, and these have typically correlated well with objective findings. We have chosen to not report the objective findings in this report as they represent only a subset of the overall cohort and may not be representative of overall outcomes. Additionally, given the difficulty in comparing severity between symptom domains, we did not use this measure in analysis.
The median follow-up time (4.4 years) is short given the range of patients who were treated from 1994 through 2009. Factors for this finding include losses to follow-up from patients who live far from our facility and to storage from paper records. Additionally, we strictly defined follow-up as the last evaluation by a radiation oncologist or a neurosurgeon, rather than the last evidence of patient being alive, in order to capture symptom outcomes. A quarter of our patients had follow-up greater than 5.8 years, permitting a limited evaluation of long term toxicity and symptom outcomes.
Fractionated stereotactic radiation therapy offers a safe and effective treatment option for patients with skull base meningiomas. Over half of patients experience durable improvement in one or more symptoms, often within a few months following the start of radiation therapy. Our results support FSRT as a safe and effective treatment for patients with base of skull meningiomas.
- Claus EB, Bondy ML, Schildkraut JM, et al.: Epidemiology of intracranial meningioma. Neurosurgery 2005, 57:1088–1095. discussion 1088–95PubMedView Article
- Whittle IR, Smith C, Navoo P, et al.: Meningiomas. Lancet 2004, 363:1535–1543.PubMedView Article
- Berger MS, Prados M: Textbook of Neuro-Oncology. 1st edition. Philadelphia: Elsevier Saunders; 2005.
- Sughrue ME, Kane AJ, Shangari G, et al.: The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. J Neurosurg 2010, 113:1029–1035.PubMedView Article
- Goldsmith BJ, Wara WM, Wilson CB, et al.: Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 1994, 80:195–201.PubMedView Article
- Mendenhall WM, Morris CG, Amdur RJ, et al.: Radiotherapy alone or after subtotal resection for benign skull base meningiomas. Cancer 2003, 98:1473–1482.PubMedView Article
- Milker-Zabel S, Zabel-du Bois A, Huber P, et al.: Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution. Int J Radiat Oncol Biol Phys 2007, 68:858–863.PubMedView Article
- Torres RC, Frighetto L, De Salles AA, et al.: Radiosurgery and stereotactic radiotherapy for intracranial meningiomas. Neurosurg Focus 2003, 14:e5.PubMedView Article
- Milker-Zabel S, Zabel A, Schulz-Ertner D, et al.: Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: Long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 2005, 61:809–816.PubMedView Article
- Milker-Zabel S, Zabel-du Bois A, Huber P, et al.: Fractionated stereotactic radiation therapy in the management of benign cavernous sinus meningiomas: long-term experience and review of the literature. Strahlenther Onkol 2006, 182:635–640.PubMedView Article
- Spiegelmann R, Cohen ZR, Nissim O, et al.: Cavernous sinus meningiomas: a large LINAC radiosurgery series. J Neurooncol 2010, 98:195–202.PubMedView Article
- Natarajan SK, Sekhar LN, Schessel D, et al.: Petroclival meningiomas: multimodality treatment and outcomes at long-term follow-up. Neurosurgery 2007, 60:965–979. discussion 979–81PubMedView Article
- Flannery TJ, Kano H, Lunsford LD, et al.: Long-term control of petroclival meningiomas through radiosurgery. J Neurosurg 2010, 112:957–964.PubMedView Article
- Minniti G, Amichetti M, Enrici RM: Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol 2009, 4:42.PubMedView Article
- Hasegawa T, Kida Y, Yoshimoto M, et al.: Long-term outcomes of Gamma Knife surgery for cavernous sinus meningioma. J Neurosurg 2007, 107:745–751.PubMedView Article
- Lee JY, Niranjan A, McInerney J, et al.: Stereotactic radiosurgery providing long-term tumor control of cavernous sinus meningiomas. J Neurosurg 2002, 97:65–72.PubMedView Article
- Pirzkall A, Debus J, Haering P, et al.: Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience. Int J Radiat Oncol Biol Phys 2003, 55:362–372.PubMedView Article
- Selch MT, Ahn E, Laskari A, et al.: Stereotactic radiotherapy for treatment of cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys 2004, 59:101–111.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.